Folic Acid
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
Folic Acid: From Vitamin B Supplementation to Biotin Metabolic Disease
One-Sentence Summary
Folic acid is a water-soluble B vitamin that is marketed in South Africa, but the registration data supplied do not state a specific approved indication. The TxGNN model predicts it may be effective for biotin metabolic disease. Only 12 clinical trials and 20 publications were retrieved, and none directly tests folic acid in this condition, so the prediction is best treated as a model output, not clinical support.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA registration data supplied |
| Predicted New Indication | Biotin metabolic disease |
| TxGNN Prediction Score | 99.49% |
| Evidence Level | L4 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 19 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Folic acid and biotin are both water-soluble B vitamins that act as cofactors or substrates in enzymatic reactions (one-carbon metabolism for folate, carboxylation reactions for biotin). Narrative reviews group them together as “vitamin-responsive disorders” (for example PMID 23622402).
This link is at the level of the vitamin class, not a drug-specific mechanism. Biotin metabolic diseases, such as biotinidase deficiency and holocarboxylase synthetase deficiency, are treated by replacing biotin, not folate. No evidence in the pack shows that folic acid corrects these defects.
The very high TxGNN score most likely reflects the closeness of vitamin nodes in the knowledge graph. It should not be read as evidence of efficacy.
Clinical Trial Evidence
The search returned 12 registered trials. None studies folic acid as a treatment for biotin metabolic disease. Most are multi-nutrient supplement studies or screening and platform studies, so folic acid’s own contribution cannot be separated out. The 10 most relevant are listed below.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01173315 | Phase 2 | Completed | 75 | Vitamin and mineral supplementation for neuropathy and nephropathy complications in type 2 diabetes. It is the only Phase 2 trial with B-vitamins, but the disease is different, so it is indirect at best. |
| NCT01643187 | Phase 2 | Unknown | 1000 | Fortified food vs milk in malnourished children. Serum and erythrocyte folic acid were among the outcomes measured. It is not a biotin disease study. |
| NCT05687474 | N/A | Completed | 6824 | Genomic newborn screening for 126 treatable genetic diseases. It is a screening programme with no folic acid intervention. |
| NCT03444155 | N/A | Completed | 30 | Pilot comparing natural and synthetic vitamin B complexes. It is small and not disease-specific. |
| NCT04312152 | N/A | Unknown | 200 | Crossover study of Q10 ubiquinol plus B and E vitamins in autism and Phelan-McDermid syndrome. It is multi-component and a different indication. |
| NCT00572741 | N/A | Completed | 39 | Nutritional intervention for oxidative stress and metabolic pathology in autism. It is multi-component and a different condition. |
| NCT03360435 | N/A | Completed | 99 | Transdermal vitamin absorption after bariatric surgery. It addresses malabsorption, not a biotin metabolic defect. |
| NCT01474486 | N/A | Completed | 40 | Multi-micronutrient intervention in heart failure palliative care. The population is unrelated. |
| NCT01558193 | N/A | Completed | 202 | Multivitamin and mineral supplementation, with or without fatty acids, on impulsivity and aggression. It is behavioural and unrelated. |
| NCT04586348 | Phase 4 | Active, not recruiting | 794 | Prenatal iodine supplementation and child neurodevelopment. It concerns a different nutrient and outcome. |
Literature Evidence
The 20 retrieved publications are mostly narrative reviews, with no randomised trials on this question. The 10 most relevant are listed below.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23622402 | 2013 | Review | Handb Clin Neurol | Covers vitamin-responsive disorders (cobalamin, folate, biotin, B1, E). It is the main source of the class-level link between folate and biotin disorders. |
| 30557456 | 2019 | Review | Mov Disord | Movement disorders in treatable inborn errors of metabolism. |
| 7027768 | 1981 | Review | Acta Vitaminol Enzymol | Vitamins in metabolic diseases, covering malabsorption, errors of vitamin metabolism and vitamin-dependent syndromes. |
| 958746 | 1976 | Not classified | Pediatr Clin North Am | Megavitamin-responsive aminoacidopathies. Supports therapeutic trials of cofactors on a case-by-case basis. |
| 779426 | 1976 | Not classified | Adv Hum Genet | Vitamin-responsive inherited metabolic disorders. No abstract available. |
| 11031989 | 2000 | Not classified | Ryoikibetsu Shokogun Shirizu | Vitamin dependency syndrome. No abstract available. |
| 38203763 | 2024 | Review | Int J Mol Sci | Vitamin B12 deficiency and the nervous system. It mentions biotin and folic acid only as related metabolic steps. |
| 37123774 | 2023 | Review | Cureus | Vitamins and diabetes. Thiamine, pyridoxine and biotin levels are lower in diabetes. |
| 25388747 | 2015 | Review | Endocr Metab Immune Disord Drug Targets | Vitamins and type 2 diabetes. Similar findings on B-vitamin levels. |
| 39828265 | 2025 | Umbrella review | Asia Pac J Clin Nutr | Water-soluble vitamins and glycaemic control in type 2 diabetes. It is not about biotin metabolic disease. |
South Africa Market Information
The 5 main registrations are listed below. Several are multi-ingredient products in which folic acid is one component. The registration data supplied contain no approved indication text or manufacturer, and Essential Medicines List (EML) status is not included.
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| A40/22.2/0592 | Gulf folic acid | Tablet | Not stated in the data supplied |
| H0689 (ACT 101/1965) | Autrin | Capsule | Not stated in the data supplied |
| G/10.1/176 | Linctifed wet cough | Syrup | Not stated in the data supplied |
| U/22.1.4/200 | Soluvit novum 10ml vials | Injection | Not stated in the data supplied |
| H2466 | Complenatal Ff | Capsule | Not stated in the data supplied |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The high TxGNN score appears to come from vitamin-cluster proximity in the knowledge graph. No trial or publication shows that folic acid treats biotin metabolic disease, whose standard treatment is biotin replacement. Drug-side information is also incomplete, since the original indication and mechanism of action are missing and safety information has not been reviewed.
To proceed, the following is needed:
- The SAHPRA package insert (warnings, contraindications and approved indications). Safety screening cannot start without it.
- Mechanism of action data, for example from DrugBank.
- Confirmation of the registered indication for the main folic acid products.
- Any evidence that folate corrects or modifies a biotin pathway defect. If none exists, the candidate should be deprioritised.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.